1) Streptococcus A group preparation
A族链球菌制剂
1.
Objective To evaluate and compare the efficacy of Streptococcus A group preparation for injection and pingyangmycin in treatment of maxillofacial hemangiomas,venous malformation and lymphatic malformation.
方法选取门诊及住院颌面部脉管瘤109例,分别采用A族链球菌制剂和平阳霉素注射治疗,对所有病例进行随访,并记录其疗效及毒副作用。
2) streptozotoein
链球菌制剂
1.
In order to explore the effect of streptozotoein on cytokines in splenocytes and serum of NOD mice,the effectiveness of streptozotoein on diabetes mellitus in mice model was studied.
为了探索链球菌制剂对NOD鼠脾细胞及血清细胞因子的影响,试验以NOD鼠为Ⅰ型糖尿病动物模型,在5~20周龄,皮下注射链球菌制剂,每只0。
3) Group A streptococcus preparation
A群链球菌制剂
1.
Treatment of 87 Cases of Giant Haemangioma with Group A Streptococcus Preparation(OK-432);
A群链球菌制剂治疗巨大海绵状血管瘤87例
2.
Objective To prepare Group A streptococcus preparation with the improved bouillon medium,and to study the LD50 and the anti-tumor activities of the preparation.
目的用改良培养基研制A群链球菌制剂,并研究其半数致死量(LD50)和抗肿瘤活性。
4) Streptococcal Preparation SM
链球菌制剂SM
1.
The Inhibition of Various Tumor Cells Growth by Streptococcal Preparation SM;
链球菌制剂SM对不同肿瘤细胞生长的抑制作用
2.
The former were given Streptococcal preparation SM or PBS,respectively.
目的 探讨链球菌制剂SM对荷瘤小鼠红细胞免疫功能的影响。
3.
Objctive To study the tumor inhibory effect of a streptococcal preparation SM and it′s effect on mice′s immune organs.
结论 链球菌制剂SM具有明显的抑瘤效应 ,其作用与环磷酰胺相比无显著性差异 ,并有促进S180荷肉瘤小鼠免疫器官增生作用。
5) Streptococcal preparation
溶血链球菌制剂
补充资料:[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式:C16H16ClN3O3S
分子量:365.5
CAS号:26807-65-8
性质:暂无
制备方法:暂无
用途:用于轻、中度原发性高血压。
分子量:365.5
CAS号:26807-65-8
性质:暂无
制备方法:暂无
用途:用于轻、中度原发性高血压。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条